Gubra A/S (GUBRA) - Total Assets
Based on the latest financial reports, Gubra A/S (GUBRA) holds total assets worth Dkr2.91 Billion DKK (≈ $455.30 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See GUBRA net asset value for net asset value and shareholders' equity analysis.
Gubra A/S - Total Assets Trend (2019–2024)
This chart illustrates how Gubra A/S's total assets have evolved over time, based on quarterly financial data.
Gubra A/S - Asset Composition Analysis
Current Asset Composition (December 2024)
Gubra A/S's total assets of Dkr2.91 Billion consist of 78.6% current assets and 21.5% non-current assets.
| Asset Category | Amount (DKK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 21.9% |
| Accounts Receivable | Dkr46.66 Million | 7.6% |
| Inventory | Dkr0.00 | 0.0% |
| Property, Plant & Equipment | Dkr0.00 | 0.0% |
| Intangible Assets | Dkr15.24 Million | 2.5% |
| Goodwill | Dkr0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Gubra A/S's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Gubra A/S stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gubra A/S's current assets represent 78.6% of total assets in 2024, an increase from 52.7% in 2019.
- Cash Position: Cash and equivalents constituted 21.9% of total assets in 2024, down from 23.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 7.6% of total assets.
Gubra A/S Competitors by Total Assets
Key competitors of Gubra A/S based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940
|
Korea | ₩18.34 Trillion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
|
Hyundai Bioscience Co. Ltd
KQ:048410
|
Korea | ₩116.62 Billion |
|
Clarity Pharmaceuticals Ltd
AU:CU6
|
Australia | AU$101.17 Million |
|
AbClon Inc
KQ:174900
|
Korea | ₩38.50 Billion |
|
Opthea Ltd
AU:OPT
|
Australia | AU$56.54 Million |
Gubra A/S - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.72 | 7.24 | 1.80 |
| Quick Ratio | 1.72 | 7.70 | 1.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Dkr1.16 Billion | Dkr424.27 Million | Dkr45.95 Million |
Gubra A/S - Advanced Valuation Insights
This section examines the relationship between Gubra A/S's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.25 |
| Latest Market Cap to Assets Ratio | 1.35 |
| Asset Growth Rate (YoY) | -2.0% |
| Total Assets | Dkr612.48 Million |
| Market Capitalization | $826.99 Million USD |
Valuation Analysis
Above Book Valuation: The market values Gubra A/S's assets above their book value (1.35x), reflecting positive investor sentiment about the company's future prospects.
Slight Asset Contraction: Gubra A/S's assets decreased by 2.0% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Gubra A/S (2019–2024)
The table below shows the annual total assets of Gubra A/S from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Dkr612.48 Million ≈ $95.83 Million |
-2.05% |
| 2023-12-31 | Dkr625.28 Million ≈ $97.83 Million |
+137.84% |
| 2022-12-31 | Dkr262.90 Million ≈ $41.13 Million |
-12.98% |
| 2021-12-31 | Dkr302.12 Million ≈ $47.27 Million |
+54.80% |
| 2020-12-31 | Dkr195.17 Million ≈ $30.54 Million |
+14.75% |
| 2019-12-31 | Dkr170.08 Million ≈ $26.61 Million |
-- |
About Gubra A/S
Gubra A/S, a biotech company, focuses on the pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases in Europe, North America, and internationally. The company operates through three segments: Pre-Clinical Contract Research (CRO), Discovery & Partnerships, and Gubra Green. It offers pre-clinical contract research and development services within metab… Read more